Steven J Bowlin

Summary

Publications

  1. doi request reprint Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents
    Steven J Bowlin
    Medco Research Institute LLC, Medco Health Solutions Inc, an Express Scripts Company, Bethesda, MD, USA
    Mayo Clin Proc 88:139-48. 2013

Detail Information

Publications1

  1. doi request reprint Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents
    Steven J Bowlin
    Medco Research Institute LLC, Medco Health Solutions Inc, an Express Scripts Company, Bethesda, MD, USA
    Mayo Clin Proc 88:139-48. 2013
    ..To describe 12-month rates and patterns of coprescription of drugs that potentially create drug-drug interactions (DDIs) through shared metabolic or transport pathways for 9 enzyme-targeted kinase inhibitor oral antineoplastic drugs (OADs)...